Long-Term Complete Response following Chemotherapy for Advanced Gastric Cancer in an Elderly Patient
A 78-year-old man was diagnosed with HER2-positive advanced gastric cancer, cT3N2M1(LYM: #16a1, 16b1), cStage ⅣB, after being referred for anemia. The lesion was deemed unresectable, and first-line chemotherapy was initiated using S-1, cisplatin(CDDP), and trastuzumab(T-mab). After 2 courses of chemotherapy, the patient developed febrile neutropenia( Grade 3). At this point, the lesion showed partial response(PR), and chemotherapy was continued using oral S-1 as a single agent. After 3 months of S-1 monotherapy, the para-aortic lymph node metastases showed a complete response (CR). S-1 monotherapy was continued without major adverse events for 2 years, and the patient is presently alive and well 6 years after obtaining clinical CR. This may suggest that S-1 is a safe and effective treatment for unresectable advanced gastric cancer in elderly patients.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:49 |
|---|---|
| Enthalten in: |
Gan to kagaku ryoho. Cancer & chemotherapy - 49(2022), 10 vom: 25. Okt., Seite 1113-1115 |
| Sprache: |
Japanisch |
|---|
| Beteiligte Personen: |
Okamoto, Shuji [VerfasserIn] |
|---|
| Themen: |
1548R74NSZ |
|---|
| Anmerkungen: |
Date Completed 26.10.2022 Date Revised 26.10.2022 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM347961754 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM347961754 | ||
| 003 | DE-627 | ||
| 005 | 20231226035054.0 | ||
| 007 | tu | ||
| 008 | 231226s2022 xx ||||| 00| ||jpn c | ||
| 028 | 5 | 2 | |a pubmed24n1159.xml |
| 035 | |a (DE-627)NLM347961754 | ||
| 035 | |a (NLM)36281605 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a jpn | ||
| 100 | 1 | |a Okamoto, Shuji |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Long-Term Complete Response following Chemotherapy for Advanced Gastric Cancer in an Elderly Patient |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 26.10.2022 | ||
| 500 | |a Date Revised 26.10.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a A 78-year-old man was diagnosed with HER2-positive advanced gastric cancer, cT3N2M1(LYM: #16a1, 16b1), cStage ⅣB, after being referred for anemia. The lesion was deemed unresectable, and first-line chemotherapy was initiated using S-1, cisplatin(CDDP), and trastuzumab(T-mab). After 2 courses of chemotherapy, the patient developed febrile neutropenia( Grade 3). At this point, the lesion showed partial response(PR), and chemotherapy was continued using oral S-1 as a single agent. After 3 months of S-1 monotherapy, the para-aortic lymph node metastases showed a complete response (CR). S-1 monotherapy was continued without major adverse events for 2 years, and the patient is presently alive and well 6 years after obtaining clinical CR. This may suggest that S-1 is a safe and effective treatment for unresectable advanced gastric cancer in elderly patients | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Cisplatin |2 NLM | |
| 650 | 7 | |a Q20Q21Q62J |2 NLM | |
| 650 | 7 | |a Tegafur |2 NLM | |
| 650 | 7 | |a 1548R74NSZ |2 NLM | |
| 650 | 7 | |a Trastuzumab |2 NLM | |
| 650 | 7 | |a P188ANX8CK |2 NLM | |
| 650 | 7 | |a Drug Combinations |2 NLM | |
| 700 | 1 | |a Ohno, Masakazu |e verfasserin |4 aut | |
| 700 | 1 | |a Koizumi, Akira |e verfasserin |4 aut | |
| 700 | 1 | |a Terai, Sachio |e verfasserin |4 aut | |
| 700 | 1 | |a Kishi, Atsuhiko |e verfasserin |4 aut | |
| 700 | 1 | |a Fujita, Tsunenori |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Gan to kagaku ryoho. Cancer & chemotherapy |d 1993 |g 49(2022), 10 vom: 25. Okt., Seite 1113-1115 |w (DE-627)NLM012601861 |x 0385-0684 |7 nnns |
| 773 | 1 | 8 | |g volume:49 |g year:2022 |g number:10 |g day:25 |g month:10 |g pages:1113-1115 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 49 |j 2022 |e 10 |b 25 |c 10 |h 1113-1115 | ||